SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

TG Therapeutics, Inc. (TGTX)

Add TGTX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/28/2017 9:33:53 AM - Followers: 49 - Board type: Free - Posts Today: 0

Great link to a string of PRs on TGTX here:


OLD R/S former Biotech info below:

About Manhattan Pharmaceuticals:

Manhattan Pharmaceuticals, Inc. (OTCBB: MHAN) is a specialty healthcare product company focused on developing and commercializing innovative treatments for underserved patient populations primarily in the areas of dermatologic disorders.  Manhattan Pharmaceuticals (through a strategic joint venture partnership with Nordic Biotech) is currently developing Hedrin, a novel, non-pesticide treatment for pediculosis (head lice) and a topical GEL for the treatment of psoriasis.

Manhattan Pharmaceuticals is located in New York City and is traded on the OTC Bulletin Board® under the ticker symbol "MHAN".


What's in the pipeline?

Hedrin™ for the Treatment of Head Lice

Hedrin is a novel, non-insecticide combination of silicones (dimethicone and cyclomethicone) that acts as a pediculicidal (lice killing) agent by disrupting the insect’s mechanism for managing fluid and breathing.  In contrast with most currently available lice treatments, Hedrin contains no chemical insecticides.  Because Hedrin kills lice by preventing the louse from excreting waste fluid, rather than by acting on the central nervous system, the insects cannot build up resistance to the treatment.  Recent studies have indicated that resistance to chemical insecticides may be increasing and therefore contributing to insecticide treatment failure.  Manhattan Pharmaceuticals believes there is significant market potential for convenient, non-insecticide treatment alternatives.  Both silicones in this proprietary formulation of Hedrin are used extensively in cosmetics and toiletries.

To date, Hedrin has been clinically studied in 362 subjects and is currently marketed as a medical device in Western Europe and as a pharmaceutical in the United Kingdom ("U.K.").
In a randomized, controlled, equivalence, clinical study (conducted in Europe), Hedrin was administered to 253 adult and child subjects with head lice infestation.  The study results, published in the British Medical Journal in June 2005, demonstrated Hedrin’s equivalence when compared to the insecticide treatment, phenothrin, the most widely used pediculicide in the U.K.  In addition, according to the same study, the Hedrin treated subjects experienced significantly less irritation (2%) than those treated with phenothrin (9%).
A clinical study published in the November 2007 issue of PLoS One, an international, peer-reviewed journal published by the Public Library of Science (PLoS), demonstrated Hedrin’s superior efficacy compared to a U.K. formulation of malathion, a widely used insecticide treatment in both Europe and North America.  In this randomized, controlled, assessor blinded, parallel group clinical trial, 73 adult and child subjects with head lice infestations were treated with Hedrin or malathion liquid.  Using intent-to-treat analysis, Hedrin achieved a statistically significant cure rate of 70% compared to 33% with malathion liquid.  Using the per-protocol analysis Hedrin achieved a highly statistically significant cure rate of 77% compared to 35% with malathion.  In Europe, it has been widely documented that head lice has become resistant to malathion, and we believe this resistance may have influenced the study results.  To date, there have been no reports of malathion resistance in the U.S.  Additionally, Hedrin treated subjects experienced no irritant reactions, and Hedrin showed clinical equivalence to malathion in its ability to inhibit egg hatching.  Overall, investigators and study subjects rated Hedrin as less odorous, easier to apply, and easier to wash out, and 97% of Hedrin treated subjects stated they were significantly more inclined to use the product again versus 31% of those using malathion.

Two new, unpublished Hedrin studies were completed by T&R in 2008.  In the first, Hedrin achieved a 100% kill rate in vitro, including in malathion resistant head lice.  In the other, a clinical field study conducted in Manisa province, a rural area of Western Turkey, Hedrin was administered to 36 adult and child subjects with confirmed head lice infestations.  Using per protocol analysis, Hedrin achieved a 97% cure rate.  Using intent-to-treat analysis, Hedrin achieved a 92% cure rate since 2 subjects were eliminated due to protocol violations.  No subjects reported any adverse events.
In the U.S., Manhattan Pharmaceuticals, through the Hedrin JV, is pursuing the development of Hedrin as a medical device.  In January 2009, the U.S. Food and Drug Administration ("FDA") Center for Devices and Radiological Health ("CDRH") notified H Pharmaceuticals that Hedrin had been classified as a Class III medical device.  A Class III designation means that a Premarket Approval ("PMA") Application will need to be obtained before Hedrin can be marketed in the U.S.  The Company expects to be required to complete at least one clinical trial as part of that PMA Application.

According to the American Academy of Pediatrics an estimated 6-12 million Americans are infested with head lice each year, with pre-school and elementary children and their families affected most often.

In February 2008, Manhattan Pharmaceuticals announced that it had entered into a joint venture agreement with Nordic Biotech Advisors ApS ("Nordic") to develop and commercialize Hedrin.  The 50/50 joint venture entity, H Pharmaceuticals, now owns, is developing, and is working to secure commercialization partners for Hedrin in North America.  Manhattan Pharmaceuticals manages the day-to-day operations of H Pharmaceuticals.  H Pharmaceuticals is independently funded and is responsible for all costs associated with the Hedrin project, including any necessary US clinical trials, patent costs, and future milestones owed to the original licensor, Thornton & Ross Ltd.


What's all this talk about a merger?

The Ariston Merger

On September 10, 2009, Manhattan entered into a non-binding letter of intent with Ariston Pharmaceuticals, Inc. ("Ariston") to acquire Ariston through a merger with a to-be-formed, wholly-owned subsidiary of Manhattan (such transaction, the "Ariston Merger").
Manhattan and Ariston contemplate the following, as set forth in the non-binding letter of intent:
After the Ariston Merger, Manhattan would own 100% of the outstanding capital stock of Ariston.
As consideration for the Ariston Merger, Manhattan would pay to the holders of Ariston capital stock, in the aggregate, shares of Manhattan common stock as follows:
at the closing of the Ariston Merger, 7,062,423 shares of Manhattan common stock (a number which represents 10% of the shares of Manhattan common stock which were issued and outstanding as of September 10, 2009, which was the date of the non-binding letter of intent); and
the right to receive additional contingent share consideration after the closing as follows:
7,062,423 additional shares of Manhattan common stock upon acceptance by the US Food and Drug Administration (“ FDA ”) of Ariston’s filing of the first New Drug Application for Ariston's AST-726 product candidate; and
8,828,029 additional shares of Manhattan common stock upon Ariston receiving FDA approval to market Ariston's AST-726 product candidate in the United States; and
8,828,029 additional shares of Manhattan common stock if there is demonstration of clinical activity and safety with the AST-914 metabolite in the current National Institutes of Health study in essential tremor patients resulting in a decision by our Board of Directors, within 12 months following the closing, to further develop the product internally or to seek a corporate partnership based on the program
Ariston would cause the holders of all outstanding Ariston convertible promissory notes to convert their notes into convertible new promissory notes to be issued by Ariston at the closing of the Ariston Merger.  The principal amount of the new notes will be equal to the lesser of the principal amount of the currently outstanding notes plus accrued and unpaid interest thereon through the date of the closing of the Ariston Merger or $15.5 million.  The new notes would have the following terms:
interest rate of 5% per annum compounding annually;
interest and principal are to be repaid from the net cash flow from AST-726 and AST 914 programs, 50% of this net cash flow will be used to repay the interest and principal. (subject to adjustment if the notes include a conversion feature and are converted.)
the holders of the new notes will have no recourse to Manhattan or any entity other than Ariston with respect to the payment of any amount under the new notes or any indebtedness which had been converted into new notes.
the new notes may include a conversion feature such that the new notes would be convertible at the option of the holder thereof into Manhattan common stock at a conversion price currently anticipated to be $.40 per share (the “ Conversion Price ”) if a sufficient number of authorized common stock is available.
At the Closing, two persons chosen by Ariston will join our Board of Directors.
Many of the important terms of the Ariston Merger remain to be negotiated between Ariston and Manhattan, and the Ariston Merger cannot take place unless and until such negotiations are completed and definitive transaction documents are prepared, approved by the boards of directors of each of Ariston and Manhattan, and signed by each of Ariston, Manhattan, and Manhattan's merger subsidiary.  In addition, the non-binding letter of intent conditions the Ariston Merger upon the approval of the stockholders of Ariston, the approval of the required percentage of noteholders of Ariston and the issuance of the new notes on the terms described in the non-binding letter of intent; and upon Manhattan raising $2.5 million of financing through the sale of debt and/or equity securities.  
Who is Ariston Pharmaceuticals, Inc.?

Ariston Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the acquisition, clinical development and rapid commercialization of human therapeutics in the Neurology area.

The Company is currently developing three clinical-stage compounds for application in four clinical indications. Prototypes of each product have shown evidence of efficacy and safety in previous clinical studies. Ariston intends to develop specialty sales and marketing capabilities to launch some of these products in the US market.


Ariston's Pipeline:

AST-726: Migraine prevention

The lead compound, AST-726, is a nasal reformulation of a well-established and very safe vitamin B12 treatment and is expected to enter Phase II clinical trials in Europe for migraine prevention in 2006. A GMP formulation of AST-726 successfully completed Phase I studies in 2005 in the US.

Migraine affects 30 million or more people in the US. Acute migraine medications such as the successful triptans help some patients. However, roughly 40% of attacks are not completely resolved by such acute medications and many patients with cardiovascular problems can not take triptans. Some patients have attacks so frequently that acute treatment is not sufficient. Therefore, up to 11 million patients in the US are candidates for safe preventative medications, such as AST-726, to reduce severity and frequency of attacks.

AST-726 is also expected to enter Phase III trials in 2007 for maintaining healthy vitamin B12 levels. Vitamin B12 deficiency affects 1-3% of the US general population and particularly the elderly. Existing first line therapies for this indication require chronic intramuscular injections, often for life.

AST-117: Anxiety

AST-117 is an oral drug for the treatment of anxiety states. In vitro, animal and human clinical studies indicate that AST-117 could provide a safer and effective alternative to leading anxiety drugs.

AST-914: Movement Disorder

AST-914 is an oral drug for the treatment of a highly prevalent movement disorder. In vitro, animal and human clinical studies indicate that AST-914 could provide a safe and effective treatment for this disorder which currently has very few treatment options.


Stock Information:

Manhattan Pharmaceuticals, Inc.

Stock Symbol: MHAN.OB


Estimated Market Cap

$5,791,187 as of Oct 27, 2009

Outstanding Shares

70,624,232 as of Nov 9, 2007

Number of Shareholders of Record

460 as of Mar 31, 2008


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#1058   I bet we will get some institutional investors Pip611 04/28/17 09:33:53 AM
#1057   great news gregque 04/28/17 09:06:22 AM
#1056   Jefferies initiates with a buy rating and a biotechnician 04/25/17 02:59:02 PM
#1055   ASCO booth #2062 June 2-6 across from MERCK. biotechnician 04/12/17 11:24:35 PM
#1054   I think they're presenting the p2 data for Selett 04/10/17 11:00:16 AM
#1053   We need some news to get this baby Pip611 04/10/17 06:28:32 AM
#1052   What does MS mean again? Lol Pip611 03/27/17 08:56:02 AM
#1051   possible. Android 2-73 03/26/17 11:58:11 PM
#1050   Conference first week of April and MS data biotechnician 03/26/17 08:49:26 PM
#1049   im looking for the MS indication to be Android 2-73 03/22/17 02:39:08 PM
#1048   I certainly hope it is approved, for financial postmeridiem 03/22/17 01:07:02 PM
#1047   Thanks for doing that. An SPA doesn't mean Android 2-73 03/22/17 12:26:16 PM
#1046   Regarding the SPA(s): postmeridiem 03/22/17 12:01:35 PM
#1045   The whole market got crushed. Remember this was Pip611 03/21/17 05:56:57 PM
#1044   getting decimated today and the last few days Android 2-73 03/21/17 03:47:42 PM
#1042   why the sell off again? Down since $15. Android 2-73 03/20/17 10:17:00 AM
#1041   It is possible. There does not have postmeridiem 03/17/17 04:40:00 PM
#1040   That's not possible. There has to be an Android 2-73 03/17/17 04:04:20 PM
#1039   To me, that means they no longer have postmeridiem 03/17/17 02:17:56 PM
#1038   From the annual 8K on 03/10/2017 on Android 2-73 03/17/17 12:48:41 PM
#1037   TGTX amended the GENUINE trial to evaluate only postmeridiem 03/17/17 10:42:43 AM
#1036   Yeah this is probably about the end of Android 2-73 03/17/17 10:20:21 AM
#1035   I'm on the road today so I can't Selett 03/17/17 10:19:13 AM
#1034   Corrupt MM's forcing price down on 5:1 buys pgh_maulers 03/17/17 10:15:53 AM
#1033   you cant just change the SPA and twiddly Android 2-73 03/17/17 09:59:07 AM
#1032   Do you have a link to that information, postmeridiem 03/17/17 09:49:33 AM
#1031   Added to my position. Severely undervalued here. I Android 2-73 03/17/17 09:48:17 AM
#1030   which leads me to believe it will be Android 2-73 03/17/17 09:39:11 AM
#1029   They didn't 'arbitrarily' scrap the recent SPA, they Selett 03/17/17 09:34:17 AM
#1028   TGTX has not mentioned the "Fast Track" designation postmeridiem 03/17/17 08:12:30 AM
#1027   The million dollar question is is that enough Pip611 03/17/17 06:06:49 AM
#1026   They did not give any details on why postmeridiem 03/16/17 10:23:09 PM
#1025   Did they explain how they can reduce the cost? Extremist223 03/16/17 09:23:00 PM
#1024   During the presentation, TGTX compared TG-1101 to ocrelizumab postmeridiem 03/16/17 06:46:49 PM
#1023   How does b cell depletion work in solid Extremist223 03/16/17 06:28:39 PM
#1022   i think they play an equally important role. Android 2-73 03/16/17 04:55:09 PM
#1021   Do you think B cells play a larger Extremist223 03/16/17 04:24:40 PM
#1020   in theory the killer T cells should be Android 2-73 03/16/17 04:14:45 PM
#1019   Positive MS data (which i think is likely) Android 2-73 03/16/17 04:13:03 PM
#1018   that makes sense logically. Android 2-73 03/16/17 04:05:50 PM
#1017   Great move this week and on the start pgh_maulers 03/16/17 04:01:35 PM
#1016   From the presentation it seems they have fewer Extremist223 03/16/17 02:06:26 PM
#1015   Higher highs daily! Loving it! Jess070283 03/16/17 10:09:19 AM
#1014   TGTX implied all the B-cell depleting drugs work postmeridiem 03/16/17 08:55:48 AM
#1013   How fast can Ocrevus lower B-cell count? Extremist223 03/15/17 11:20:50 PM
#1012   You are 100% correct and your question is Selett 03/15/17 07:43:35 PM
#1011   That is absolutely incredible. After the first infusion. Extremist223 03/15/17 06:23:42 PM
#1010   Can't link it but it's in their latest Selett 03/15/17 05:47:00 PM
#1009   I think that antibodies against the myelin sheath Extremist223 03/15/17 04:31:45 PM
#1008   TGTX is a beast Pip611 03/15/17 04:26:24 PM